Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| IBM | JPMorgan Chase | Pfizer | |
|---|---|---|---|
| Moat rating | narrow IBM's FY2025 10-K describes "a highly competitive environment" with "hundreds of competitors" and says IBM is "regularly exposed to new competitors" as it executes its hybrid-cloud/AI strategy, while differentiating through "incumbency with enterprises" and "client relationships and trust" — a real but narrow moat, not a wide one. | wide The 2025 Form 10-K opens with a balance sheet and a licensing perimeter that a new entrant cannot assemble: $4.4 trillion in assets and $362.4 billion in stockholders' equity at December 31, 2025, a principal bank subsidiary (JPMorgan Chase Bank, N.A.) with branches in 48 states and Washington, D.C., 318,512 employees across 66 countries, and consolidated supervision as a bank and financial holding company by the Federal Reserve, layered with the OCC, FDIC, SEC, FINRA, CFTC, U.K. PRA/FCA and the ECB over its principal subsidiaries. Item 1 also notes the Bank Holding Company Act restricts holding companies to banking and closely-related activities, so the charter itself is scarce. Rated wide rather than higher because Item 1's own Competition paragraph calls the environments 'highly competitive' and names e-commerce, digital-asset and financial-technology entrants that 'disintermediate traditional banking products'. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | switching costs The 10-K roots IBM's differentiation in "incumbency with enterprises" and "client relationships and trust" — installed-base lock-in across its hybrid-cloud platform (Red Hat) and enterprise software and infrastructure raises switching costs. | cost scale The filing's durable advantage is scale rather than a proprietary technology or a stated network effect: $4.4 trillion of assets and $362.4 billion of equity, 318,512 employees, a 48-state branch footprint and a GSIB capital and liquidity regime administered under the Basel III framework. Item 1A repeatedly frames technology as a required expenditure - 'New technologies have required and could require JPMorganChase to increase expenditures to modify its products' and possible 'significant investments in technology' for quantum-resistant encryption - which is a fixed cost the firm spreads over a base few competitors match. The filing asserts no network effect and no switching-cost lock-in. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | fast follower An enterprise incumbent that differentiates via "incumbency with enterprises" but is "regularly exposed to new competitors" in its hybrid-cloud/AI push (FY2025 10-K) — a follower in the current AI cycle rather than its leader. | co leader Item 1 claims the firm is 'a leader' in five distinct businesses at once, and 'a leading financial services firm based in the United States' - but it claims to be 'a leader', never the leader, and names no rank or peer comparison anywhere in Item 1 or Item 1A. Scale disclosed in the filing (assets, equity, 318,512 employees, 66 countries, CCB 144,196 / CIB 94,563 / AWM 29,722 headcount) puts it in the front rank; the document itself supports a co-leader reading and not a sole-leader one. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate Gross margin is high and rising (54.9% FY2021 to 58.2% FY2025) on a software-mix shift, but "price" is a principal method of competition per the 10-K and consulting/infrastructure remain price-competitive. | moderate Item 1 states the businesses 'generally compete on the basis of the quality and variety of the Firm's products and services, transaction execution, innovation, reputation and price' - price is one of several axes, not absent. Item 1A is explicit that 'Actions by competitors could put pressure on the pricing for JPMorganChase's products and services or could cause it to lose market share, particularly with respect to investment products and traditional banking products,' and separately that higher rates can cause 'the loss of deposits, including where customers transition to higher-yielding products.' The filing states no margin trend supporting stronger pricing power. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | IBM's moat rests on deep enterprise incumbency — sticky installed-base relationships across hybrid cloud (Red Hat), enterprise software, and mission-critical infrastructure, plus brand and a large patent base. But its own FY2025 10-K frames "a highly competitive environment" with "hundreds of competitors" and says IBM is "regularly exposed to new competitors" as it pursues hybrid cloud and AI, so the moat is durable but narrow and contested in the AI/cloud growth arena. | Item 1 describes JPMorganChase as 'a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management' operating off a $4.4 trillion balance sheet with $362.4 billion of equity as of December 31, 2025. The protection is the combination of that scale with a regulatory perimeter - Federal Reserve consolidated supervision, a national bank charter under the OCC, and separately licensed broker-dealer and credit-institution subsidiaries in the U.K. and Germany - that bounds who may offer the same product set. The filing is candid that the perimeter is leaking at the edges: it names non-depository and internet-only entrants offering lending, payments processing, cryptocurrency and stablecoins, tokenized securities and algorithmic investment advice, and warns of 'disruption to payments processing... from the use of new technologies that may not require intermediation'. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | A hybrid-cloud platform, enterprise-AI (watsonx), and consulting provider to large enterprises — a software/cloud layer of the AI stack. | An AI adopter and a possible AI casualty, not an AI supplier: the filing books no AI revenue line and mentions no data-center or model exposure, and instead carries a dedicated risk factor on 'the development of advanced technologies such as AI' warning of 'competitive disadvantage if competitors are able to deploy AI more quickly or effectively' and of 'replacement or disintermediation of direct customer relationships if AI agents autonomously manage or intermediate financial decisions' - so its AI exposure as filed is defensive and operational rather than a supply-chain position. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm bearish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |